icon-    folder.gif   Conference Reports for NATAP  
  (APASL) 24th Conference of the Asian Pacific
Association for the Study of the Liver
12-15 March, 2014
Brisbane, Australia
Back grey_arrow_rt.gif
Simeprevir plus peginterferon/ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection: Results from the Phase III TIGER study conducted in East Asian patients living in China and Korea
  Reported by Jules Levin
APASL 2015
24th Conference of the Asian Pacific Association for the Study of the Liver (APASL), 12-15 March 2015, Istanbul, Turkey
Wei L1, Han T2, Yang D3, Heo J4, Shang J5, Cheng J6, Chen X7, Xie Q8, Kim J9, Kalmeijer R10, Ouwerkerk-Mahadevan S11, Lenz O12, Sinha R13, Li M14, Scott J15, Peeters M12, Witek J13
1Peking University People's Hospital and Peking University Hepatology Institute and Peking Key Laboratory for Hepatitis C and Immune Therapy, Beijing, China; 2Tianjin Third Central Hospital, Tianjin, China; 3Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 4Pusan National University and Medical Research Institute, Busan, Republic of Korea; 5Henan Provincial People's Hospital, Zhengzhou, China; 6Beijing Ditan Hospital, Capital Medical University, Beijing, China; 7Beijing You An Hospital, Capital Medical University, Beijing, China; 8Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; 9Gachon University Gil Medical Center, Incheon, Republic of Korea; 10Janssen Global Services LLC, Titusville, NJ, USA; 11Janssen Research & Development BVBA, Beerse, Belgium; 12Janssen Infectious Diseases BVBA, Beerse, Belgium; 13Janssen Research & Development LLC, Titusville, NJ, USA; 14China R&D and Scientific Affairs, Xi'an Janssen Pharmaceutical Company, Beijing, China; 15Janssen Global Services, LLC, High Wycombe, UK